asjos77 Posted - 19 minutes ago

$HALO I'm confused, +30% grower trading for 10x fwd PE? that's crazy cheap. Anybody have insight into why such a discount?

Sean29md Posted - 3 hours ago

$HALO This BARGAIN will not last forever: 2024 PE Estimates 12.41 2025 PE Estimates 10.34 2026 PE Estimates 7.8 PEG .43 https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios Institutional ownership 98.8% https://www.nasdaq.com/market-activity/stocks/halo/institutional-holdings

RoacHK1LLaH420 Posted - 3 hours ago

$SGMO $EXTR $CLOV $HALO 💪🤑 Stay strong MID TERMS and LONG TERMS. We start 2025 on the right foot.

NVDAMillionaire Posted - 15 hours ago

$HALO Halozyme Therapeutics (HALO): Transforming Drug Delivery with Pioneering Innovations https://beyondspx.com/article/halozyme-therapeutics-halo-transforming-drug-delivery-with-pioneering-innovations

RoacHK1LLaH420 Posted - 3 days ago

$TNXP $TSLA $HALO 😂🤣😂 no problem!

RoacHK1LLaH420 Posted - 4 days ago

$HALO You know I'm still in here. I haven't sold. Just bought some more. 💪🤑

RoacHK1LLaH420 Posted - 4 days ago

$TNXP $HALO $NVDA $NFLX $PLTR Market is going GREEN!💪🤑

DaveTradesLIVE Posted - 4 days ago

$HALO selling pressure persisting on this one for near term. Expect a final sell sequence to 45.85 gap fill target before it breaks out to 53.8 for tp1 Longer term targets in 2025 will be at 70-72 range

Sean29md Posted - 4 days ago

$HALO Ask yourself what would be the shareprice be when: 1) HVAI deal is announced 2) US Enhanze patent is extended to 2029 3) Alteogen agrees (or is compelled to) pay licensing fees to Halo 4) OPDIVO SC is approved North of $80

Sean29md Posted - 5 days ago

$HALO Loading up more. Current PE is 15. Forward PE is 10. PEG OF 0.4 https://finviz.com/quote.ashx?t=HALO&p=d

Sean29md Posted - 6 days ago

$HALO $halo Halozyme Therapeutics Price Target Maintained With a $68.00/Share by HC Wainwright & Co.

moorenard1 Posted - 1 week ago

$HALO Holding up very well with $XBI and just about every biotech getting killed...

Stocksrunner Posted - 1 week ago

Short interest is plummeting for $ASAN, $HALO, and $CSL. Is this the start of a bullish run? 🤔 stocksrunner.com/posts/2024-12-12-Short-Interest-Shifts

detwin Posted - 2 weeks ago

$HALO is back

DaveTradesLIVE Posted - 2 weeks ago

$HALO updated price forecast for near term. Expecting continued volatility before FOMC & then a sizable push higher into close of month/monthly option contract exp

Sean29md Posted - 2 weeks ago

$HALO Take home message from Helen's Q&A session today: 1) they are not in a rush to buy another company anytime soon. They will take their time. 2) multiple companies interested in new Enhanze and HVAI deals 3) Helen sounded very confident that Halozyme will prevail against Merck's post patent challenge on one of Halozyme's Modified hyaluronidases. Helen said halozyme was prepared for this already as this is a typical move by a company (Merck) who knows their in violation of another company's patents. Helen said halozyme will prevail not only in this challenge but also because they have a number of other patents in the MDASE portfolio of patents that Alteogen/Merck are in violation of. The most likely outcome is that Alteogen will pay halozyme for licensing MDASE. Win-win for all.

RoacHK1LLaH420 Posted - 2 weeks ago

$TNXP $EXTR $HALO

Sean29md Posted - 2 weeks ago

$HALO CEO and CFO, please reassure investors today during your presentations that halozyme will not buy another comapny until we have a HVAI deal. Buy some shares on the open market.

RoacHK1LLaH420 Posted - 3 weeks ago

$TNXP $PLTR $ADMA $HOOD $HALO No stress. Just keep BUYING on the DIPS.

Sean29md Posted - 11/29/24

$HALO HALO forward guidance for Earnings Per Share (from Oct earnings call): 2024 Guidance: $4.00 - $4.20 2025 Guidance: $4.45 - $4.85 2026 Guidance: $5.70 - $6.20 2027 Guidance: $7.15 - $7.75 2028 Guidance: $7.50 - $8.10 If you assuming zero growth (absurd, I know) in EPS for 2029, 2030 and 2031 and add all these EPS's up, you will get to a 6-year EPS range of $51.36-$55.4 Cash is $5/share and debt is $8/share. If you add the EPS for the next 6 years plus the cash/share and subtract the debt, you get to a range of $48.36-$52.4. This calculation assumes no new Enhanze deals, no HVAI, no MDASE licensing income and losing the litigation against Alteogen. This will also assume that all future hyaluronidase deals will go to Alteogen and zero deals to Halo (also absurd). At its current share price, halo is trading under the value of its next 6 years of earnings plus cash minus debt. It is an excellent buy here, regardless of the noise around patent fight with Alteogen/Merck.

Alon_R Posted - 11/28/24

@dave2ta I tend to agree. I didn't object that if it is a swift deal. I Just specified that "tomorrow"(maybe even in less than a year)it might be too late for $Halo to purchase Xeris for any near that value, or at all. After all, certain fulfillment of Xeriject tech + XP-8121 + Recorlev + Gvoke in a few years = Halozyme current value. For 2, maybe 2.5 Billion (if Xeris into it at all), Halozyme possibly going to double it worth in a few years.

Estimize Posted - 11/27/24

Wall St is expecting 1.17 EPS for $HALO Q4 [Reporting 02/25 AMC] http://www.estimize.com/intro/halo?chart=historical&metric_name=eps&utm_co

Alon_R Posted - 11/27/24

@BarbarianTrades For $Halo sake, they better purchase, rounded and ready to leap company as Xeris for $2B, than Evotec for $1.5B. It's no-brainer. Xeris would double Halozyme's worth in a matter of 4-5 Years. Xeriject&Xerisol Tech, Recorlev, Gvoke, once-weekly XP-8121. Only question is if Xeris will agree to $2B now, when it could be Halozyme size company in 4-5 years. Let's see. Interesting. If I'm Halozyme, I don't argue about the cost, while I know Xeris purchasing may have double my value in a timely manner.

BarbarianTrades Posted - 11/27/24

$XERS M&A speculation moving the stock after $HALO backs out of 1.5B $EVO deal is my guess

RoacHK1LLaH420 Posted - 11/27/24

$TNXP I'm ready for those DIPS! Just sold 5 $HALO at $48. Show me does dips baby.

Sean29md Posted - 11/27/24

$HALO HALO forward guidance for Earnings Per Share (Non-GAAP Diluted EPS): 2023 Actual: $2.77 2024 Guidance (6/6): $3.65 - $4.05 2024 Guidance (10/31): $4.00 - $4.20 2025 Guidance: $4.45 - $4.85 2026 Guidance: $5.70 - $6.20 2027 Guidance: $7.15 - $7.75 2028 Guidance: $7.50 - $8.10 2023-2028 CAGR: 23%

Sean29md Posted - 11/27/24

$HALO where are the insider buys at these absurdly low valuations for Halozyme?

Optionshmoptions Posted - 11/26/24

$HALO wtf is this garbage action

Optionshmoptions Posted - 11/26/24

$HALO low volume bleeding

Sean29md Posted - 11/26/24

$HALO It takes a bit of time for people to understand what is going on. Halozyme's projected EPS through 2030 is intact regardless of 1) whether halozyme wins its patent infringement lawsuit against Alteogen or 2) whether Merck can successfully apeal halo's MDASE patent. Why? MDASE is/would be icing on the cake. The EPS projections by halo have not included any revenues from MDASE licensing or winning infringement penalties from Alteogen. MDASE was intriduced to the publice just a few weeks ago and halo did not update their 5 year projections after MDASE introduction. Even if Halozyme doesn't get a dime from MDASE or legal case against Alteogen, it will still deliver a EPS CAGR of 25% for next 5 years.